Dr Mitchell Lawrence
Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology
133 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.
DOI: 10.1186/s13046-026-03763-x2026
Journal article
Abstract 427: PMR-116, a second-generation RNA polymerase I inhibitor displaying therapeutic efficacy in a broad spectrum of malignancies.
DOI: 10.1158/1538-7445.am2026-4272026
Journal article
Abstract 2697: Single-cell transcriptomic characterisation reveals pathway determinants of bipolar androgen therapy response in prostate cancer.
DOI: 10.1158/1538-7445.am2026-26972026
Journal article
Single-Cell Morphomechanics of Prostate Cancer-Associated Fibroblasts Identifies Distinct Features Associated with Patient Outcome
DOI: 10.1002/advs.2025224402026
Journal article
A0396 Tumour cell evolution within patient-derived models of localised hereditary prostate cancer
DOI: 10.1016/s0302-2838(26)00451-32025
Journal article
Single-cell transcriptomics redefines focal neuroendocrine differentiation as a distinct prostate cancer pathology
DOI: 10.1002/1878-0261.700992025
Journal article
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
DOI: 10.1016/j.euf.2025.03.017
RECENT SCHOLARLY WORKS
2025
Journal article
77P PMR-116, a second generation ribosome biogenesis inhibitor, displays antitumour activity in a wide range of preclinical cancer models and on-target activity in a phase I trial
DOI: 10.1016/j.esmoop.2025.1054272025
Journal article
PD12-14 NOVEL IMMUNOHISTOCHEMICAL PROFILE TO PREDICT RESPONSE TO INTRAVESICAL BACILLUS CALMETTE–GUÉRIN (BCG) IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
DOI: 10.1097/01.ju.0001109848.08748.9e.142025
Journal article
Abstract 7182: EZH2 inhibition as a therapeutic strategy for castration resistant prostate cancer in combination with AR-antagonist enzalutamide
DOI: 10.1158/1538-7445.am2025-7182